Pharmacoepidemiology and drug safety
-
Pharmacoepidemiol Drug Saf · Jun 2013
Non-steroidal anti-inflammatory drugs and venous thromboembolism in women.
Non-steroidal anti-inflammatory drugs (NSAIDs) might increase the risk of venous thromboembolism (VTE), and risks might differ by type of NSAID. Compared with men, women have a higher incidence of VTE at younger age, and they more often use NSAIDs. ⋯ We found no increased risks of VTE in association with use of NSAIDs. Users of high cumulative doses of acetic acid derivatives and coxibs had the highest risks, suggesting a relationship with cyclooxygenase selectivity and dose.
-
Pharmacoepidemiol Drug Saf · May 2013
Improving adverse drug event detection in critically ill patients through screening intensive care unit transfer summaries.
This study aimed to determine the frequency and type of adverse drug events (ADEs) identified in intensive care unit (ICU) transfer summaries and in the hospital discharge summaries to demonstrate the effectiveness of ICU transfer summary surveillance in the identification of ADEs. ⋯ The use of ICU transfer summaries is an effective tool to increase ADE detection. The use of an ICU transfer summary should be considered as an adjunct method to an existing ADE surveillance system for heightened pharmacovigilance.
-
Pharmacoepidemiol Drug Saf · May 2013
The EU-ADR Web Platform: delivering advanced pharmacovigilance tools.
Pharmacovigilance methods have advanced greatly during the last decades, making post-market drug assessment an essential drug evaluation component. These methods mainly rely on the use of spontaneous reporting systems and health information databases to collect expertise from huge amounts of real-world reports. The EU-ADR Web Platform was built to further facilitate accessing, monitoring and exploring these data, enabling an in-depth analysis of adverse drug reactions risks. ⋯ A pioneering workspace that helps in explaining the biological path of adverse drug reactions was developed within the EU-ADR project consortium. This tool, targeted at the pharmacovigilance community, is available online at https://bioinformatics.ua.pt/euadr/.
-
Pharmacoepidemiol Drug Saf · Apr 2013
Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy.
Information on the risk of upper gastrointestinal complications (UGIC) in users of nimesulide, the most used nonsteroidal anti-inflammatory drug (NSAID) in Italy, is scarce. In the context of the European regulatory review on nimesulide, we estimated and compared the risk associated with nimesulide and other individual NSAIDs with the risk in nonusers. ⋯ IRs of UGIC in FVG decreased about 50% between 2001 and 2008. Nimesulide was in the low-medium range of RR. A complete ascertainment of UGIC cases in databases may require validation of nonspecific codes, secondary codes, and additional codes such as peritonitis and acute posthemorrhagic anemia.
-
Pharmacoepidemiol Drug Saf · Apr 2013
High correlations between levels of consumption and mortality related to strong prescription opioid analgesics in British Columbia and Ontario, 2005-2009.
Prescription opioid analgesic (POA)-related burden of disease - including mortality - is high and constitutes a major public health problem in the US and Canada. Associations between the overall levels of POA consumption and key related morbidity indicators in the population have been demonstrated. We examined potential correlations between levels of consumption of four commonly used POAs and related mortality in British Columbia (BC) and Ontario. ⋯ Our findings of strong correlations between select POA use and mortality levels reflect similar evidence from elsewhere on correlations between POA consumption and morbidity or mortality indicators. In the context of high and increasing levels of POA consumption in Canada, efforts to reduce POA-related mortality may require a comprehensively revised approach towards more appropriate and safer prescribing to reduce POA use volumes together with more effective monitoring of POA medications.